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have assessed its value on cardiovascular outcomes in a broad, worldwide population.
OBJECTIVES The aim of this study was to determine whether PP is associated with major adverse cardiovascular
outcomes, independently of mean arterial pressure.
METHODS Participants from the international REACH (Reduction of Atherothrombosis for Continued Health) registry,
which evaluates subjects with clinical atherothrombotic disease or risk factors for its development, were examined. Those
with incomplete 4-year follow-up or PP data (ﬁnal n ¼ 45,087) were excluded. Univariate and multivariate regression
analyses were performed to determine the association between PP and cardiovascular outcomes, including cardiovascular
death, nonfatal myocardial infarction, nonfatal stroke, all myocardial infarction, all stroke, cardiovascular hospitalization,
and a combined outcome. PP was analyzed as a continuous and categorical (i.e., by quartile) variable.
RESULTS The mean age of the cohort was 68  10 years, 35% were women, and 81% were treated for hypertension.
The mean blood pressure was 138  19/79  11 mm Hg, rendering a mean PP of 49  16 mm Hg. On univariate analysis,
increasing PP quartile was associated with worse outcomes (p < 0.05 for all comparisons). After adjusting for sex, age,
current smoking status, history of hypercholesterolemia, history of diabetes, aspirin use, statin use, blood pressure
medication use, and mean arterial pressure, PP quartile was still associated with all outcomes except all stroke and
cardiovascular death (p < 0.05 for all comparisons). Analysis of PP as a continuous variable yielded similar results.
CONCLUSIONS In an international cohort of high-risk subjects, PP, a readily available hemodynamic parameter, is
associated with multiple adverse cardiovascular outcomes and provides prognostic utility beyond that of mean arterial
pressure. (J Am Coll Cardiol 2016;67:392–403) © 2016 by the American College of Cardiology Foundation.m the aBrigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts;
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AB BR E V I A T I O N S
AND ACRONYM S
BMI = body mass index
DBP = diastolic blood pressure
MI = myocardial infarction
PP = pulse pressure
= systolic blood pressure
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393P ulsatile components of blood pressure captureelements of cardiac risk beyond that capturedby steady components (1–3). The former, often
measured as pulse pressure (PP), is recognized as a
potent risk factor for cardiovascular disease,
including myocardial infarction (MI), stroke, and car-
diovascular mortality (4). According to the Windkes-
sel model of arterial blood pressure, PP can be
thought simply as a reﬂection of both stroke volume
and arterial wall compliance. Although left ventricu-
lar ejection contributes, high PP typically reﬂects
decreased arterial compliance, particularly in older
patients. Hypertension, diabetes, atherosclerosis,
and many more conditions alter the cellular matrix
of the wall, reducing wall elasticity, and thus their
relationship to elevation in PP becomes clear.SEE PAGE 404Several studies have examined the relationship in
speciﬁc populations between PP and adverse cardio-
vascular outcomes, with the preponderance of evi-
dence favoring an association (4–11). However, there
are few data regarding the predictive value of PP for
cardiovascular outcomes in a large, international
cohort. In addition, peripheral PP, although clinically
more accessible than central PP, may not be the most
accurate reﬂection of left ventricular stress and cor-
onary perfusion (10). Thus, understanding whether
peripheral PP is clinically useful warrants further
study. Finally, although a signiﬁcant proportion,
though certainly not all (12,13), of the PP data have
been generated from hypertensive clinical trials with
restricted patient populations, less is known about its
relationship to a broad array of subjects in an outpa-
tient setting. We therefore sought to examine the
relationship between PP and adverse cardiovascular
events using data from the REACH (Reduction of
Atherothrombosis for Continued Health) registry.GlaxoSmithKline, Ipsen, Menarini, Merck Serono, Merck Sharpe & Dohme, No
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STUDY POPULATION. We studied participants
from the REACH registry, an international,
longitudinal study of atherothrombosis. De-
tails regarding the methodology of the study
have been previously reported (14–17). In
brief, REACH enrolled stable outpatients $45
years of age with either established atherothrombotic
disease (coronary artery disease, cerebrovascular
disease, or peripheral artery disease) or with $3 risk
factors for atherothrombosis. Subjects were recruited
during a 7-month period between December 2003
and June 2004. Because of regulatory requirements,
enrollment in Japan was delayed and occurred be-
tween August 2004 and December 2004. Final data
collection occurred until April 2009. Exclusion criteria
for the present study were lack of either a complete
set of blood pressure measurements or 4 years of
follow-up data. Complete follow-up of the initial
cohort could not be completed because of withdrawal
of some of the study sites. All REACH study partici-
pants gave written informed consent, and each study
site’s local Institutional Review Board approved the
REACH study.
CLINICAL CHARACTERISTICS AND OUTCOME VARIABLES.
Baseline height, weight, and seated systolic blood
pressure (SBP) and diastolic blood pressure (DBP)
were obtained. Blood pressure was measured using
a brachial mercury sphygmomanometer. PP was
deﬁned as the difference between the SBP and DBP. A
quality control check with the number of blood
pressure readings ending in zero was performed (18)
and showed that 58% of SBP readings and 60% of
DBP readings ended in zero (20% expected). Body
mass index (BMI) was deﬁned as weight in kilograms
divided by the square of height in meters. Medical
history and medications were established using
SBPvartis, Pileje, Roche, Sanoﬁ, Servier, and Takeda. Dr.
ate Cardiology, Medscape Cardiology, Regado Bio-
titute and the Society of Cardiovascular Patient Care;
g Committee; is a member of the data monitoring
earch Institute, the Mayo Clinic, and the Population
of Cardiology (senior associate editor, Clinical Trials
er), the Duke Clinical Research Institute (clinical trial
eering committee), HMP Communications (editor-in-
of Cardiology (associate editor and section editor,
ering committee), Slack Publications (chief medical
ion steering committees); is deputy editor of Clinical
l-Myers Squibb, Eisai, Ethicon, Forest Laboratories,
d has conducted unfunded research for FlowCo, PLx
lationships relevant to the contents of this paper to
is paper.
Selvaraj et al. J A C C V O L . 6 7 , N O . 4 , 2 0 1 6
Pulse Pressure and Cardiovascular Outcomes F E B R U A R Y 2 , 2 0 1 6 : 3 9 2 – 4 0 3
394techniques previously documented (14). In particular,
diabetes was deﬁned as any history of diabetes or
current diabetes (diagnosed by at least 2 fasting blood
glucose measures >7 mmol/l or >126 mg/dl), treated
or not. Hypercholesterolemia was deﬁned as treat-
ment with lipid-lowering therapy. Hypertension was
deﬁned as past or current treatment with antihyper-
tensive agents. The primary outcome of the study
was a combined outcome of cardiovascular death
(including fatal MI and fatal stroke), nonfatal MI,
nonfatal stroke, and cardiovascular hospitalization.
Secondary outcomes included each of the individual
outcomes used to formulate the primary outcome in
addition to fatal and nonfatal MI as well as fatal and
nonfatal stroke. Reasons for cardiovascular hospital-
ization included atherothrombotic events, such as
transient ischemic attack, unstable angina, and other
ischemic arterial events. Further elaboration of the
deﬁnitions of these outcomes is provided elsewhere
(14,16).
STATISTICAL ANALYSIS. Clinical characteristics are
displayed by PP quartile, for descriptive purposes.
Continuous data are presented as mean  SD. Cate-
gorical variables are presented as counts and per-
centages. Cox proportional hazard models were
constructed to determine the relationship of PP
(per 10 mm Hg increase) with all outcomes. Cutoff
ranges for each of the PP quartiles were deﬁned as
follows: quartile 1, #50 mm Hg; quartile 2, 50 <PP
#60 mm Hg; quartile 3, 60 <PP #70 mm Hg; and
quartile 4, >70 mm Hg. Figure 1 displays the raw
relationship between PP quartiles and cardiovascular
outcomes. Given the nonlinear relationship observed
in a few of the analyses, adjusted Cox models for each
outcome with PP introduced as restricted cubic
splines were performed using knots at PP ¼ 40, 60,
and 80 mm Hg (Figure 2) (19).
Covariates included in multivariate models were
selected on the basis of clinical relevance as well as
association with PP in previous studies. Model 1
covariates included sex, age, current smoker status,
history of hyperlipidemia, history of diabetes melli-
tus, aspirin use, and statin use. Model 2 further
adjusted for history of atherothrombosis (deﬁned as
history of MI, stroke, or peripheral artery disease).
Model 3 additionally adjusted for medications known
to inﬂuence PP, including angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers,
beta-blocker, calcium-channel blockers, and diuretic
agents. Finally, model 4 additionally adjusted for
mean arterial pressure (deﬁned as: [2 DBP þ SBP] / 3)
to determine whether PP adds clinically useful
information beyond these parameters (20).On sensitivity analyses, we analyzed the results
only including: 1) women, for whom PP data are
limited in the published research; 2) subjects >60
years of age, for whom the relationship with PP
is typically stronger (4); 3) subjects without estab-
lished atherothrombotic disease; 4) subjects with
SBP >140 mm Hg (vs. #140 mm Hg); and 5) subjects
treated for hypertension versus those not treated
for hypertension, given the reduction of PP with
antihypertensive treatment (21).
All primary analyses were repeated using SBP and
DBP as the predictor variables instead of PP. A 2-sided
p value #0.05 was considered to indicate statistical
signiﬁcance. Analysis was performed using SAS
version 9.3 (SAS Institute Inc., Cary, North Carolina).
RESULTS
CHARACTERISTICS OF STUDY PARTICIPANTS.
Descriptive characteristics of the REACH study sam-
ple are displayed in Table 1. Among an eligible 67,888
participants, more than two-thirds (n ¼ 45,087) met
the inclusion criteria and were analyzed in the pre-
sent study. The vast majority of exclusions were due
to incomplete 4-year follow-up data (n ¼ 22,661). The
mean age of the cohort was 68  10 years, and 35%
were women. Subjects from 29 countries were repre-
sented. Comorbidities were common, including hy-
pertension (81%), hypercholesterolemia (70%),
coronary artery disease (58%), and diabetes mellitus
(44%); 82% had established atherothrombotic dis-
ease. Long-term medication use reﬂected standard
therapies used for the comorbidities detailed in
Table 1. Blood pressure was relatively well controlled
(mean 138  19/79  11 mm Hg; mean PP 49  16
mm Hg) and obesity was common (mean BMI 28  5
kg/m2, 28% obese [BMI >30 kg/m2]). Increasing PP
was associated with increasing age, BMI, and female
sex. There was a signiﬁcant difference in comorbidity
burden proﬁle in the lower and higher PP quartiles.
Higher PP quartiles were more likely to have hyper-
tension, peripheral arterial disease, and diabetes (p <
0.01 for all comparisons). Lower PP quartiles were
associated with increasing prevalence of congestive
heart failure, coronary artery disease, smoking, hy-
percholesterolemia, and atrial ﬁbrillation (p < 0.05
for all comparisons). Medication difference likewise
reﬂected the disparity in comorbidity burden (i.e.,
higher antiplatelet agent, nitrate or antianginal agent,
statin, and beta-blocker use with lower PP quartiles;
p < 0.01 for all comparisons). Online Table 1 shows
the distribution of PP by SBP tiers (<140,
140 #PP <160, and $160 mm Hg). Of note, 93% of
subjects in PP quartile 4 had SBP $140 mm Hg.
FIGURE 1 Pulse Pressure Quartiles and Cardiovascular Outcomes
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Unadjusted relationship between pulse pressure quartiles and outcomes (p < 0.01 for trend of all outcomes). Mean pulse pressure (millimeters
of mercury) is labeled on the x-axis for each pulse pressure quartile.
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FIGURE 2 Continuous Relationship Between Pulse Pressure and Cardiovascular Outcomes
1.4
1.3
1.2
1.1
1.0
0.9
0.8
Ha
za
rd
 R
at
io
s (
95
%
 C
I)
40 50 60 70 80
PULSE PRESSURE (mm Hg)
1.4
1.3
1.2
1.1
1.0
0.9
0.8
Ha
za
rd
 R
at
io
s (
95
%
 C
I)
40 50 60 70 80
PULSE PRESSURE (mm Hg)
1.4
1.3
1.2
1.1
1.0
0.9
0.8
Ha
za
rd
 R
at
io
s (
95
%
 C
I)
40 50 60 70 80
PULSE PRESSURE (mm Hg)
1.4
1.3
1.2
1.1
1.0
0.9
0.8
Ha
za
rd
 R
at
io
s (
95
%
 C
I)
40 50 60 70 80
PULSE PRESSURE (mm Hg)
1.4
1.3
1.2
1.1
1.0
0.9
0.8
Ha
za
rd
 R
at
io
s (
95
%
 C
I)
40 50 60 70 80
PULSE PRESSURE (mm Hg)
1.4
1.3
1.2
1.1
1.0
0.9
0.8
Ha
za
rd
 R
at
io
s (
95
%
 C
I)
40 50 60 70 80
PULSE PRESSURE (mm Hg)
1.4
1.3
1.2
1.1
1.0
0.9
0.8
Ha
za
rd
 R
at
io
s (
95
%
 C
I)
40 50 60 70 80
PULSE PRESSURE (mm Hg)
CARDIOVASCULAR DEATH CARDIOVASCULAR HOSPITALIZATION
FATAL AND NONFATAL MYOCARDIAL INFARCTION NONFATAL MYOCARDIAL INFARCTION
FATAL AND NONFATAL STROKE NONFATAL STROKE
COMBINED OUTCOME
Pulse pressure as a continuous variable is nonlinearly associated with cardiovascular death, fatal and nonfatal stroke, and the combined
outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular hospitalization (p < 0.05 for nonlinearity).
However, pulse pressure is linearly associated with nonfatal myocardial infarction, fatal and nonfatal myocardial infarction, nonfatal stroke, and
cardiovascular hospitalization (p ¼ 0.95, p ¼ 0.70, p ¼ 0.14, and p ¼ 0.84 for nonlinearity, respectively). CI ¼ conﬁdence interval.
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TABLE 1 Clinical Characteristics of the Study Sample
All Cohort
(N ¼ 45,087)
Quartiles of PP (mm Hg)
First Quartile
(PP #50 mm Hg)
(n ¼ 10,153)
Second Quartile
(50 <PP #60 mm Hg)
(n ¼ 11,842)
Third Quartile
(60 <PP #70 mm Hg)
(n ¼ 11,061)
Fourth Quartile
(PP >70 mm Hg)
(n ¼ 12,031)
Age, yrs 68.41  9.97 65.29  10.35 67.71  9.98 69.24  9.64 70.99  9.11
BMI, kg/m2 27.86  5.46 27.67  5.46 27.88  5.39 27.89  5.42 28.01  5.58
Diastolic blood pressure, mm Hg 78.64  11.03 78.12  10.05 78.75  10.21 79.15  11.18 78.52  12.38
Systolic blood pressure, mm Hg 137.98  19.22 118.34  11.35 131.22  10.48 141.24  11.37 158.23  16.1
Pulse pressure, mm Hg 49.34  15.91 40.22  5.92 52.47  2.93 62.09  2.77 79.71  11.29
Male 29,167 (64.71) 7,232 (71.27) 8,026 (67.79) 7,018 (63.48) 6,891 (57.28)
Region
North America 15,602 (34.60) 4,151 (40.88) 4,173 (35.24) 3,416 (30.88) 3,862 (32.10)
Latin America 1,373 (3.05) 399 (3.93) 334 (2.82) 266 (2.40) 374 (3.11)
Western Europe 14,542 (32.25) 2,481 (24.44) 3,624 (30.60) 4,138 (37.41) 4,299 (35.73)
Eastern Europe 4,523 (10.03) 1,002 (9.87) 1,232 (10.40) 1,141 (10.32) 1,148 (9.54)
Middle East 464 (1.03) 103 (1.01) 106 (0.90) 95 (0.86) 160 (1.33)
Asia 3,510 (7.78) 950 (9.36) 962 (8.12) 737 (6.66) 861 (7.16)
Japan 5,073 (11.25) 1,067 (10.51) 1,411 (11.92) 1,268 (11.46) 1,327 (11.03)
Medical history
Congestive heart failure 6,070 (13.65) 1,555 (15.50) 1,539 (13.13) 1,389 (12.74) 1,587 (13.44)
History of hypertension 36,649 (81.29) 7,131 (70.24) 9,184 (77.57) 9,249 (83.63) 11,085 (92.14)
Peripheral artery disease 5,841 (12.95) 1,046 (10.30) 1,327 (11.21) 1,498 (13.54) 1,970 (16.37)
Coronary artery disease 26,318 (58.37) 6,812 (67.09) 7,255 (61.26) 6,255 (56.55) 5,996 (49.84)
Current smoker 6,821 (15.61) 1,674 (16.96) 1,787 (15.54) 1,705 (15.95) 1,655 (14.21)
Hypercholesterolemia 31,685 (70.34) 7,371 (72.64) 8,456 (71.47) 7,695 (69.66) 8,163 (67.93)
Diabetes 19,492 (43.50) 3,779 (37.43) 4,882 (41.45) 4,876 (44.38) 5,955 (49.86)
Atrial ﬁbrillation/ﬂutter 4,571 (10.30) 1,093 (10.94) 1,183 (10.11) 1,117 (10.24) 1,178 (9.98)
Baseline medication
Angiotensin-converting enzyme inhibitors 20,345 (45.35) 4,515 (44.61) 5,147 (43.61) 4,961 (45.05) 5,722 (47.96)
Angiotensin II receptor antagonists 10,117 (22.57) 1,872 (18.52) 2,389 (20.25) 2,566 (23.33) 3,290 (27.60)
Beta-blockers 21,280 (47.39) 5,235 (51.71) 5,681 (48.08) 4,963 (45.06) 5,401 (45.19)
Calcium-channel blockers 15,742 (35.07) 2,625 (25.97) 3,813 (32.27) 4,097 (37.21) 5,207 (43.58)
Diuretic agents 18,019 (40.09) 3,590 (35.44) 4,290 (36.32) 4,475 (40.56) 5,664 (47.34)
Hypoglycemic agents 17,813 (39.52) 3,414 (33.63) 4,430 (37.42) 4,480 (40.52) 5,489 (45.64)
Acetylsalicylic acid 30,260 (67.22) 7,206 (71.10) 8,105 (68.52) 7,278 (65.92) 7,671 (63.86)
Nitrates/other antiangina agents 10,980 (24.75) 2,575 (25.75) 2,966 (25.41) 2,690 (24.74) 2,749 (23.28)
Other antihypertensive agents 4,038 (9.03) 649 (6.43) 885 (7.51) 1,039 (9.46) 1,465 (12.33)
Statins 30,683 (68.12) 7,331 (72.28) 8,222 (69.45) 7,394 (66.92) 7,736 (64.39)
Antiplatelet agents 35,690 (79.20) 8,288 (81.69) 9,489 (80.16) 8,716 (78.84) 9,197 (76.49)
Values are mean  SD or n (%). p value for all comparisons <0.01, with the exception of atrial ﬁbrillation/ﬂutter (p ¼ 0.04).
BMI ¼ body mass index; PP ¼ pulse pressure.
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EVENTS. Figure 1 displays the relationship of PP
quartiles to all outcomes, including cardiovascular
death, nonfatal MI, fatal and nonfatal MI, nonfatal
stroke, fatal and nonfatal stroke, cardiovascular hos-
pitalization, and the combined outcome (p < 0.01 for
trend). Given the J-shaped relationship between PP
and some of these outcomes, cubic splines modeling
was performed (Figure 2). Cardiovascular death, fatal
and nonfatal stroke, and the combined outcome
showed nonlinear relationships (p < 0.05) with PP,
whereas nonfatal MI, fatal and nonfatal MI, nonfatal
stroke, and cardiovascular hospitalization did not(p ¼ 0.95, p ¼ 0.70, p ¼ 0.14, and p ¼ 0.84, respec-
tively). Exclusion of participants with congestive
heart failure linearly transformed the relationship for
the combined outcome (p ¼ 0.14) but not for cardio-
vascular death (p ¼ 0.01).
Table 2 shows event rates and unadjusted and
multivariate-adjusted hazard ratios that occurred
over a 4-year follow-up period by PP quartile.
Approximately 30% experienced at least 1 of the out-
comes over this period, with the majority of events
attributed to cardiovascular hospitalization, reﬂecting
a high-risk cohort. On univariate analysis, the fourth
quartile of PP, and sometimes the third quartile, was
TABLE 2 Association of Pulse Pressure With Adverse Cardiovascular Events on Unadjusted and Multivariate-Adjusted Analyses
Outcome Event Rate, n/N (%)
Unadjusted Multivariate Adjusted*
HR 95% CI p Value HR 95% CI p Value
CV death
Quartile 1 586/10,153 (6.95) — — — — — —
Quartile 2 637/11,842 (6.58) 0.9 0.8–1.0 0.19 0.8 0.7–0.9 <0.01
Quartile 3 611/11,061 (6.63) 0.9 0.8–1.0 0.47 0.7 0.6–0.8 <0.01
Quartile 4 796/12,031 (8.09) 1.1 1.0–1.2 <0.01 0.8 0.7–0.9 <0.01
Nonfatal MI
Quartile 1 271/10,153 (3.23) — — — — — —
Quartile 2 321/11,842 (3.4) 1.0 0.8–1.1 0.90 1.0 0.8–1.2 0.47
Quartile 3 345/11,061 (3.81) 1.1 1.0–1.3 0.05 1.2 1.0–1.4 0.01
Quartile 4 408/12,031 (4.14) 1.2 1.0–1.4 <0.01 1.3 1.1–1.5 <0.01
Fatal and nonfatal MI
Quartile 1 399/11,068 (4.73) — — — — — —
Quartile 2 474/11,407 (4.98) 1.0 0.8–1.1 0.84 1.0 0.9–1.1 0.60
Quartile 3 508/12,821 (5.52) 1.1 1.1–1.3 0.01 1.1 0.9–1.3 0.05
Quartile 4 580/9,791 (5.86) 1.2 1.0–1.4 <0.01 1.1 1.0–1.3 0.03
Nonfatal stroke
Quartile 1 368/10,153 (4.46) — — — — — —
Quartile 2 480/11,842 (4.89) 1.1 0.9–1.2 0.11 1.0 0.8–1.1 0.91
Quartile 3 517/11,061 (5.77) 1.2 1.1–1.4 <.01 1.1 0.9–1.2 0.12
Quartile 4 632/12,031 (6.33) 1.4 1.2–1.6 <.01 1.2 1.0–1.3 <0.01
Fatal and nonfatal stroke
Quartile 1 448/10,153 (5.36) — — — — — —
Quartile 2 577/11,842 (5.86) 1.1 0.9–1.2 0.12 0.9 0.8–1.1 0.82
Quartile 3 592/11,061 (6.57) 1.2 1.0–1.3 <0.01 1.0 0.9–1.1 0.64
Quartile 4 743/12,031 (7.4) 4 1.2–1.5 <0.01 1.1 0.9–1.2 0.05
CV hospitalization
Quartile 1 1,929/10,153 (21.54) — — — — — —
Quartile 2 2,203/11,842 (21.16) 0.9 0.9–1.0 0.37 1.0 0.9–1.0 0.63
Quartile 3 2,231/11,061 (22.92) 1.0 1.0–1.1 0.03 1.1 1.0–1.1 <0.01
Quartile 4 2,611/12,031 (24.63) 1.1 1.0–1.2 <.01 1.1 1.1–1.2 <0.01
CV death/MI/stroke/hospitalization
Quartile 1 2,619/10,153 (29.27) — — — — — —
Quartile 2 3,008/11,842 (28.81) 0.9 0.9–1.0 0.40 0.9 0.9–1.0 0.53
Quartile 3 2,993/11,061 (30.6) 1.0 1.0–1.1 0.04 1.0 0.9–1.0 0.25
Quartile 4 3,548/12,031 (33.4) 1.1 1.1–1.2 <.01 1.1 1.0–1.1 <0.01
*Multivariate model adjusted for sex; age; current smoking status; history of hypercholesterolemia, diabetes, or atherothrombosis; and aspirin, statin, angiotensin-converting
enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker, or diuretic agent use.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; HR ¼ hazard ratio; MI ¼ myocardial infarction.
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398associated with increasing risk for all individual as
well as combined adverse cardiovascular events. On
multivariate analysis, the fourth quartile of PP showed
a signiﬁcant increase in the risk for all outcomes
except fatal and nonfatal stroke (p value nonsigniﬁ-
cant) but also for cardiovascular death, for which the
relationship was inverted and higher PP quartile was
protective (p <0.05). Given the discrepancy in co-
morbidity proﬁle, further adjustment for coronary
artery disease and congestive heart failure was per-
formed, which abolished this trend for cardiovascular
death (p ¼ 0.14 for PP quartile 4).
Figure 3 demonstrates the strength of these asso-
ciations per 10 mm Hg increase in PP, including bothunivariate and multivariate models. On univariate
analysis, increasing PP was associated with worse
outcomes (p < 0.01 for all outcomes). After adjust-
ment for several potential confounding factors
(model 1; covariates: sex, age, current smoking status,
history of hypercholesterolemia, history of diabetes,
aspirin use, and statin use), PP was still associated
with all outcomes, except cardiovascular death.
Additional adjustments in models 2 (covariates: his-
tory of stroke, MI, and peripheral arterial disease) and
3 (covariates: use of angiotensin-converting enzyme
inhibitor, angiotensin receptor blocker, beta-blocker,
calcium-channel blocker, or diuretic agent) yielded
similar results.
FIGURE 3 Forest Plot of Pulse Pressure and Cardiovascular Outcomes Using Univariate and Multivariate Analysis
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Forest plots showing the relationship between pulse pressure, per 10 mm Hg increase, with several cardiovascular (CV) outcomes on univariate and
multivariate analysis. Refer to the “Methods” section for a complete listing of covariates included for analysis. CI ¼ conﬁdence interval; MI ¼ myocardial
infarction.
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399To determine whether PP adds prognostic infor-
mation over mean arterial pressure, model 4 was
performed (Figure 3). After additionally adjusting for
mean arterial pressure, the relationships between PP
and adverse events persisted for nonfatal MI, fatal
and nonfatal MI, cardiovascular hospitalization, and
the combined outcome (p < 0.01).
SUBGROUP ANALYSES. Sensitivity analyses were
conducted in several subgroups, and these results are
displayed as forest plots in Online Figures 1 to 7.
When comparing estimates derived from model 4, the
relationship between PP and adverse events varied by
subgroup. In women, the only association that was
signiﬁcant was observed between PP and nonfatal MI(p < 0.01). For participants greater than 60 years of
age, associations were observed with nonfatal MI
(p < 0.01), fatal and nonfatal MI (p < 0.01), and car-
diovascular hospitalization (p ¼ 0.02). For partici-
pants without established atherothrombotic disease,
several statistically signiﬁcant associations were
found, including increasing risk with increasing PP
for the following outcomes: nonfatal stroke, fatal and
nonfatal stroke, cardiovascular hospitalization, and
the combined outcome (p < 0.01 for all comparisons).
When stratifying by SBP levels using 140 mm Hg as
the cutoff, the relationships between PP and nonfatal
MI as well as the combined outcome were signiﬁcant
in hypertensive patients (p # 0.05 for both
CENTRAL ILLUSTRATION Pulse Pressure and Adverse Cardiovascular Events: Findings From the REACH Registry
0                         0.8                  0.9                1.0                 1.1                 1.2
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Selvaraj, S. et al. J Am Coll Cardiol. 2016; 67(4):392–403.
Unadjusted hazard ratios with 95% conﬁdence intervals (CIs) are depicted per 10 mm Hg increase in pulse pressure for all adverse cardio-
vascular (CV) outcomes. The combined outcome comprises CV death, myocardial infarction (MI), stroke, or CV hospitalization.
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400comparisons). In nonhypertensive patients,
increasing PP was associated with higher risk for
nonfatal MI and cardiovascular hospitalization but
was protective against all stroke and cardiovascular
death (p < 0.05 for all comparisons). Finally, when
stratifying by antihypertensive treatment, increasing
PP was associated with higher risk for cardiovascular
hospitalization, all MI, and the combined outcome.
However, in the untreated group, higher PP was
associated with lower risk for nonfatal stroke and all
stroke (p < 0.01 for all comparisons).
ASSOCIATION OF SBP AND DBP WITH ADVERSE
CARDIOVASCULAR EVENTS. Data regarding the
relationship between both SBP and DBP and adverse
outcomes are presented in the Online Appendix.
Similar to PP, increase in SBP quartile (particularly
the fourth quartile) was associated with worsened
outcomes in multivariate analysis (Online Table 2)
(p < 0.05 for all comparisons except fatal and nonfatal
MI). The complex relationship with cardiovascular
death was similarly observed with SBP as was
observed with PP (19). Similar adjustment for pres-
ence of coronary artery disease and congestive heart
failure weakened, but did not abolish, the relation-
ship (p ¼ 0.04). The fourth quartile of DBP was
associated with increasing risk for nonfatal stroke,
fatal and nonfatal stroke, cardiovascular hospitaliza-
tion, and the composite outcome (Online Table 3)
(p # 0.01 for all comparisons). However, quartile 2was protective against nonfatal MI, fatal and nonfatal
MI, cardiovascular hospitalization, and the combined
outcome. In addition, all quartiles aside from the
referent quartile were protective against cardiovas-
cular death. Adjustment of all quartiles for coronary
artery disease and congestive heart failure elimi-
nated the relationship with cardiovascular death
(p ¼ 0.06).
DISCUSSION
In a large, international registry of >45,000 partic-
ipants with established or at high risk for arterial
disease, we found that higher PP conferred an
increased risk for multiple adverse cardiovascular
events (Central Illustration). The adverse relation-
ships persisted between PP and several adverse
outcomes, notably the combined outcome of car-
diovascular death, cardiovascular hospitalization,
nonfatal MI, and nonfatal stroke, after controlling for
several potential confounding risk factors, including
mean arterial pressure. Our study is among the largest
international studies of PP and adds further support to
the prognostic utility of PP. In addition, the REACH
registry offers a contemporary analysis of the rela-
tionship between PP and adverse cardiovascular
events, which is important given the change in
patterns of cardiovascular disease in the past few
decades (22).
J A C C V O L . 6 7 , N O . 4 , 2 0 1 6 Selvaraj et al.
F E B R U A R Y 2 , 2 0 1 6 : 3 9 2 – 4 0 3 Pulse Pressure and Cardiovascular Outcomes
401Furthermore, given the large population and sig-
niﬁcant number of events, we were able to perform
multiple sensitivity analyses to deﬁne more precisely
the relationship between PP and adverse events in
several subgroups. Of note, strong relationships were
observed in participants without established athero-
thrombotic disease, suggesting that despite being
lower risk, PP still has strong prognostic value. In
participants older than 60 years of age, PP was asso-
ciated with nonfatal MI and cardiovascular hospital-
ization. As shown previously, PP is particularly useful
in older patients, because SBP and DBP tend to
diverge after age 55 (23). Therefore, the resultant PP
widening becomes a more accurate assessment of
vascular bed compliance and cardiovascular risk.
The degree of SBP, we found, was also important.
In hypertensive patients, there were signiﬁcant in-
creases in nonfatal MI and the combined outcome.
However, in nonhypertensive subjects, this relation-
ship with cardiovascular outcomes was mixed.
Increasing PP was associated with higher risk for
nonfatal MI and cardiovascular hospitalization;
however, it was also protective against fatal and
nonfatal stroke and, as a result, cardiovascular death,
likely secondary to the resultant relationship be-
tween stroke and low DBP with widening PP (24). Two
studies from the Framingham cohort found that PP
independently predicted cardiovascular disease but
that elevated SBP was an important modifying risk
factor in the relationship (25,26). Finally, antihyper-
tensive treatment also inﬂuences the relationship
between PP and adverse events. For patients on
treatment for hypertension, there was an increased
risk for cardiovascular hospitalization, all MI, and the
combined endpoint. For patients not on treatment for
hypertension, increasing PP was protective again
against nonfatal stroke and all stroke, which is again
likely secondary to lower stroke risk with lower DBP.
It is important to note that these adverse re-
lationships observed in the entire study population
were most prominent with the fourth quartile of PP
(corresponding to a PP of >70 mm Hg) and sometimes
with the third quartile. The vast majority of patients
in the fourth quartile of PP were hypertensive
(SBP $140 mm Hg), while nearly one-half were very
hypertensive (SBP $160 mm Hg). Thus, it is particu-
larly notable that this quartile of PP continued to
have signiﬁcant associations with numerous adverse
events even after adjusting for mean blood pressure.
In addition, some of these relationships were J sha-
ped (including cardiovascular death, all stroke, and
the combined outcome). Thus, high PP states likely
reﬂect adverse hemodynamic status, whereas low PP
is not necessarily reassuring, because the latter mayindicate poor perfusion states. This hypothesis was
further explored by removing patients with heart
failure, which linearly transformed the relationship
for the combined outcome, suggesting that low PP
may be most problematic in this group and likely re-
ﬂects low stroke volume (27).
Despite several studies on the topic, there is still
some debate as to whether PP adds to cardiovascular
risk stratiﬁcation. The Framingham Heart Study
showed in a cohort of nearly 2,000 participants that
neither SBP nor DBP was superior to PP in predicting
coronary events (4). However, this cohort was
initially free of coronary heart disease and not taking
antihypertensive medications. Conversely, in MRFIT
(Multiple Risk Factor Intervention Trial), PP was,
interestingly, found to be inferior to SBP and DBP in
cardiovascular risk assessment in male patients free
of diabetes mellitus and MI (11). The cohort analyzed
in the present study was at higher risk than these
other cohorts, with a predominantly hypertensive
population and many with established athero-
thrombosis. Our ﬁndings of the additive utility of PP
are consistent with other studies in higher risk pop-
ulations (19,20).
The pathophysiologic correlates of elevated PP are
complex. Increasing PP causes increased cyclic
stretch on vascular structures. These changes in
intramural tension catalyze numerous pathways,
including atherosclerotic remodeling, facilitate
proinﬂammatory cell migration, and increase oxidant
production (1). Although increasing PP clearly accel-
erates atherothrombosis, the reverse is also true,
whereby plaque formation increases vascular stiff-
ness, and thereby PP, creating a vicious cycle. Previ-
ous study of peripheral PP has yielded inconsistent
results in relation to adverse cardiovascular events.
The large sample size of the present study provided
enough power to detect a relationship. The relative
risks for adverse events calculated here are compa-
rable with those observed in previous studies (20,28).
We also examined the relationship between both
SBP and DBP and adverse cardiovascular events. PP
and SBP followed similar trends, as changes in PP
quartiles largely reﬂect changes in SBP. In addition,
there were J-shaped relationships between DBP and a
few outcomes, including the combined outcome,
which is consistent with a large, previous study in
patients with atherothrombosis, in whom low blood
pressure may not be ideal (19,29). Low diastolic pres-
sure may be poorly tolerated because this may reﬂect
reduced coronary ﬁlling, which predominantly occurs
during diastole. Conversely, low DBP may reﬂect
“reverse causality,” wherein low pressure is a symp-
tom of the disease, not a cause, and therefore may
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: PP, which can arise as a
consequence of arterial stiffness in patients with
atherosclerosis, is a marker of cardiovascular disease
burden and identiﬁes patients at risk for ischemic
events irrespective of age, sex, SBP, antihypertensive
therapy, or previous atherothrombotic events.
TRANSLATIONAL OUTLOOK: Future studies
should assess the outcomes of therapies that specif-
ically target long-term reduction of arterial PP.
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402represent a sicker population (30). Furthermore, PP
continued to show a more linear relationship with
stroke, as seen previously (19,31). The discrepant re-
lationships between SBP and DBP and adverse car-
diovascular events stress the importance of
calculating PP. However, our ﬁndings are not meant to
support the isolated use of PP. As also demonstrated
in the Framingham Heart Study, the combined use of
both static (i.e., SBP or mean arterial pressure) and
dynamic (i.e., PP) measurements best captures car-
diovascular risk (32).
Current guidelines for the management of hyper-
tension have focused on SBP and DBP (33). PP has
previously been identiﬁed as providing prognostic
value even beyond the previous iteration of the Joint
National Committee classiﬁcation for hypertension
(3). In addition, normal mean arterial pressure can
still signify increased cardiovascular risk in the
setting of high PP (34). Because PP is easily calculated
from blood pressure, its clinical utility is high.
Reduction in PP may serve as a therapeutic target;
however, future research is necessary to delineate its
role more precisely.
STUDY LIMITATIONS. Our results should be inter-
preted in the context of several limitations. First,
central PP may provide physiologically more relevant
information than peripheral measurements, because
proximal measurements capture effects perceived by
the heart as well as the coronary and carotid arteries.
However, obtaining these data requires special de-
vices not amenable to routine clinical practice; in
addition, a recent meta-analysis showed that central
PP does not offer a signiﬁcant increase in predictive
ability over peripheral PP (28).
Second, heart rate was not collected and therefore
could not be adjusted for on multivariate analysis.
Third, REACH studied high-risk subjects with
clinical atherothrombotic disease or multiple risk
factors for atherothrombosis. Therefore, our results
may not be generalizable to healthier cohorts. How-
ever, we performed subgroup analysis in subjects
without established atherothrombosis, and many
adverse relationships were still observed.
Fourth, REACH did not identify subjects with se-
vere aortic stenosis, which could explain the rela-
tionship between low PP and increased cardiovascularmortality even after excluding patients with heart
failure.
Fifth, the REACH registry does not provide ambu-
latory blood pressure measurements, which have
been shown to improve cardiovascular risk stratiﬁ-
cation (35).
Sixth, our study demonstrated digit preference
bias, reﬂected by the higher than expected number of
blood pressure readings ending in zero, which has
been observed in numerous previous studies (36–38).
It is not clear if this affected our results, but it does
underscore the need for better training in the mea-
surement of blood pressure in clinical practice.
CONCLUSIONS
In a large study of high-risk subjects with risk factors
for, or established, atherothrombosis, PP adds valu-
able information in cardiovascular risk stratiﬁcation
to standard risk factors, including mean arterial pres-
sure. These results are particularly relevant because
the population reﬂects many modern clinical prac-
tices, given the large burden of atherothrombotic dis-
ease studied here. PP, which is readily available in the
ofﬁce setting, can help risk stratify high-risk patients.
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